Hyon K. Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hyon K. Choi has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Gary Curhan
Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
2 shared publicationsA Eftekhari
Radiology Department, Department of Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, Canada
1 shared publicationA M Al-Arfaj
Division of Rheumatology, Vancouver General Hospital, University of British Columbia, Vancouver, Canada
1 shared publication- A. Elisabeth Hak
Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
1 shared publication Andrew J. Luk
Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, WA, USA
1 shared publicationArathi R. Setty
Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
1 shared publication
Latest Publications
- 1 October 2009
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 68 (10) , 1609-1612
Dual energy computed tomography in tophaceous gout
Objective: To evaluate the potential utility of a dual energy CT (DECT) scan in assessing urate deposits among patients with tophaceous gout, and obtain computerised quantification of tophus volume in peripheral joints. Methods: 20 consecutive patients with tophaceous gout and 10 control patients with other arthritic conditions were included. DECT scans were performed using a renal stone colour-coding protocol that specifically assessed the chemical composition of the material (ie, urate coloured in red, calcium coloured in blue). An automated volumetric assessment of DECT was used to measure the volume of urate deposits in all peripheral joint areas. Results: All 20 patients with gout showed red colour-coded urate deposits on their DECT scans, whereas none of 10 controls showed urate deposits. DECT scans revealed a total of 440 areas of urate deposition in 20 patients, whereas physical examination showed 111 areas of urate deposition (mean 22 vs 6 per patient, respectively, p3 to 249.13 cm3, with a mean of 40.20 cm3. Conclusions: DECT scans can produce obvious colour displays for urate deposits and help to identify subclinical tophus deposits. Furthermore, tophus volume can be measured by DECT scans through an automated volume estimation procedure.
- 1 October 2009
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 68 (10) , 1609-1612
Dual energy computed tomography in tophaceous gout
Objective: To evaluate the potential utility of a dual energy CT (DECT) scan in assessing urate deposits among patients with tophaceous gout, and obtain computerised quantification of tophus volume in peripheral joints. Methods: 20 consecutive patients with tophaceous gout and 10 control patients with other arthritic conditions were included. DECT scans were performed using a renal stone colour-coding protocol that specifically assessed the chemical composition of the material (ie, urate coloured in red, calcium coloured in blue). An automated volumetric assessment of DECT was used to measure the volume of urate deposits in all peripheral joint areas. Results: All 20 patients with gout showed red colour-coded urate deposits on their DECT scans, whereas none of 10 controls showed urate deposits. DECT scans revealed a total of 440 areas of urate deposition in 20 patients, whereas physical examination showed 111 areas of urate deposition (mean 22 vs 6 per patient, respectively, p3 to 249.13 cm3, with a mean of 40.20 cm3. Conclusions: DECT scans can produce obvious colour displays for urate deposits and help to identify subclinical tophus deposits. Furthermore, tophus volume can be measured by DECT scans through an automated volume estimation procedure.
- Open Access
- 15 May 2009
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 48 (7) , 804-806
Allopurinol and mortality in hyperuricaemic patients
Objectives. While studies have suggested that gout and hyperuricaemia are associated with the risk of premature death, none has investigated the role of urate-lowering therapy on this critical outcome. We examined the impact of allopurinol, the most commonly used urate-lowering drug, on the risk of mortality in hyperuricaemic patients. Methods. From a population of hyperuricaemic veterans of [serum urate level >416 μmol/l (7.0 mg/dl)] at least 40 years of age, we compared the risk of death between incident allopurinol users (n = 2483) and non-users (n = 7441). We estimated the multivariate mortality hazard ratio (HR) of allopurinol use with Cox proportional hazards models. Results. Of the 9924 veterans (males, 98% and mean age 62.7 years), 1021 died during the follow-up. Patients who began treatment with allopurinol had worse prognostic factors for mortality, including higher BMI and comorbidities. After adjusting for baseline urate levels, allopurinol treatment was associated with a lower risk of all-cause mortality (HR 0.78; 95% CI 0.67, 0.91). Further adjustment with other prognostic factors did not appreciably alter this estimate (HR 0.77; 95% CI 0.65, 0.91). The mean change from baseline in serum urate within the allopurinol group was −111 μmol/l (−1.86 mg/dl). Adjusting for baseline urate level, allopurinol users had a 40 μmol/l (0.68 mg/dl) lower follow-up serum urate value than controls (95% CI −0.55, −0.81). Conclusion. Our findings indicate that allopurinol treatment may provide a survival benefit among patients with hyperuricaemia.
- 15 May 2009
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 48 (7) , 804-806
Open AccessAllopurinol and mortality in hyperuricaemic patients
Objectives. While studies have suggested that gout and hyperuricaemia are associated with the risk of premature death, none has investigated the role of urate-lowering therapy on this critical outcome. We examined the impact of allopurinol, the most commonly used urate-lowering drug, on the risk of mortality in hyperuricaemic patients. Methods. From a population of hyperuricaemic veterans of [serum urate level >416 μmol/l (7.0 mg/dl)] at least 40 years of age, we compared the risk of death between incident allopurinol users (n = 2483) and non-users (n = 7441). We estimated the multivariate mortality hazard ratio (HR) of allopurinol use with Cox proportional hazards models. Results. Of the 9924 veterans (males, 98% and mean age 62.7 years), 1021 died during the follow-up. Patients who began treatment with allopurinol had worse prognostic factors for mortality, including higher BMI and comorbidities. After adjusting for baseline urate levels, allopurinol treatment was associated with a lower risk of all-cause mortality (HR 0.78; 95% CI 0.67, 0.91). Further adjustment with other prognostic factors did not appreciably alter this estimate (HR 0.77; 95% CI 0.65, 0.91). The mean change from baseline in serum urate within the allopurinol group was −111 μmol/l (−1.86 mg/dl). Adjusting for baseline urate level, allopurinol users had a 40 μmol/l (0.68 mg/dl) lower follow-up serum urate value than controls (95% CI −0.55, −0.81). Conclusion. Our findings indicate that allopurinol treatment may provide a survival benefit among patients with hyperuricaemia.
- Open Access
- 26 September 2008
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 10 (5) , 1-7
Menopause, postmenopausal hormone use and serum uric acid levels in US women – The Third National Health and Nutrition Examination Survey
Introduction: Despite the substantial prevalence of gout in the ageing female population, female hormonal influence has not been comprehensively examined. We evaluated and quantified the potential independent association between menopause, postmenopausal hormone use and serum uric acid levels in a nationally representative sample of women. Methods: Using data from 7662 women aged 20 years and older in the Third National Health and Nutrition Examination Survey (1988 to 1994), we examined the relation between menopause, postmenopausal hormone use and serum uric acid levels. We used multivariate linear regression to adjust for other risk factors for hyperuricaemia such as dietary factors, age, adiposity, alcohol use, renal function, hypertension and diuretic use. Results: Menopause was associated with higher serum uric acid levels. After adjusting for covariates, serum uric acid levels among women with natural menopause and surgical menopause were greater than premenopausal women by 0.34 mg/dl (95% confidence interval [CI], 0.19 to 0.49) and 0.36 mg/dl (95% CI, 0.14 to 0.57), respectively. Current postmenopausal hormone use was associated with a lower serum uric acid level among postmenopausal women (multivariate difference, 0.24 mg/dl [95% CI, 0.11 to 0.36]). The serum uric acid levels increased with increasing age categories (crude difference between 20 to 29 years and 70 years and over = 1.03 mg/dl, p for trend < 0.001), but this increase was not present after adjusting for other covariates (p for trend = 0.66). Conclusions: These findings from a nationally representative sample of US women indicate that menopause is independently associated with higher serum uric acid levels, whereas postmenopausal hormone use is associated with lower uric acid levels among postmenopausal women. The age-associated increase in serum uric acid levels in women may be explained by menopause and other age-related factors.
- 26 September 2008
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 10 (5) , 1-7
Open AccessMenopause, postmenopausal hormone use and serum uric acid levels in US women – The Third National Health and Nutrition Examination Survey
Introduction: Despite the substantial prevalence of gout in the ageing female population, female hormonal influence has not been comprehensively examined. We evaluated and quantified the potential independent association between menopause, postmenopausal hormone use and serum uric acid levels in a nationally representative sample of women. Methods: Using data from 7662 women aged 20 years and older in the Third National Health and Nutrition Examination Survey (1988 to 1994), we examined the relation between menopause, postmenopausal hormone use and serum uric acid levels. We used multivariate linear regression to adjust for other risk factors for hyperuricaemia such as dietary factors, age, adiposity, alcohol use, renal function, hypertension and diuretic use. Results: Menopause was associated with higher serum uric acid levels. After adjusting for covariates, serum uric acid levels among women with natural menopause and surgical menopause were greater than premenopausal women by 0.34 mg/dl (95% confidence interval [CI], 0.19 to 0.49) and 0.36 mg/dl (95% CI, 0.14 to 0.57), respectively. Current postmenopausal hormone use was associated with a lower serum uric acid level among postmenopausal women (multivariate difference, 0.24 mg/dl [95% CI, 0.11 to 0.36]). The serum uric acid levels increased with increasing age categories (crude difference between 20 to 29 years and 70 years and over = 1.03 mg/dl, p for trend < 0.001), but this increase was not present after adjusting for other covariates (p for trend = 0.66). Conclusions: These findings from a nationally representative sample of US women indicate that menopause is independently associated with higher serum uric acid levels, whereas postmenopausal hormone use is associated with lower uric acid levels among postmenopausal women. The age-associated increase in serum uric acid levels in women may be explained by menopause and other age-related factors.
- Top Cited Papers
Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study
Objective To examine the relation between intake of sugar sweetened soft drinks and fructose and the risk of incident gout in men. Design Prospective cohort over 12 years. Setting Health professionals follow-up study. Participants 46 393 men with no history of gout at baseline who provided information on intake of soft drinks and fructose through validated food frequency questionnaires. Main outcome measure Incident cases of gout meeting the American College of Rheumatology survey criteria for gout. Results During the 12 years of follow-up 755 confirmed incident cases of gout were reported. Increasing intake of sugar sweetened soft drinks was associated with an increasing risk of gout. Compared with consumption of less than one serving of sugar sweetened soft drinks a month the multivariate relative risk of gout for 5-6 servings a week was 1.29 (95% confidence interval 1.00 to 1.68), for one serving a day was 1.45 (1.02 to 2.08), and for two or more servings a day was 1.85 (1.08 to 3.16; P for trend=0.002). Diet soft drinks were not associated with risk of gout (P for trend=0.99). The multivariate relative risk of gout according to increasing fifths of fructose intake were 1.00, 1.29, 1.41, 1.84, and 2.02 (1.49 to 2.75; P for trend Conclusions Prospective data suggest that consumption of sugar sweetened soft drinks and fructose is strongly associated with an increased risk of gout in men. Furthermore, fructose rich fruits and fruit juices may also increase the risk. Diet soft drinks were not associated with the risk of gout.
Top Cited PapersSoft drinks, fructose consumption, and the risk of gout in men: prospective cohort study
Objective To examine the relation between intake of sugar sweetened soft drinks and fructose and the risk of incident gout in men. Design Prospective cohort over 12 years. Setting Health professionals follow-up study. Participants 46 393 men with no history of gout at baseline who provided information on intake of soft drinks and fructose through validated food frequency questionnaires. Main outcome measure Incident cases of gout meeting the American College of Rheumatology survey criteria for gout. Results During the 12 years of follow-up 755 confirmed incident cases of gout were reported. Increasing intake of sugar sweetened soft drinks was associated with an increasing risk of gout. Compared with consumption of less than one serving of sugar sweetened soft drinks a month the multivariate relative risk of gout for 5-6 servings a week was 1.29 (95% confidence interval 1.00 to 1.68), for one serving a day was 1.45 (1.02 to 2.08), and for two or more servings a day was 1.85 (1.08 to 3.16; P for trend=0.002). Diet soft drinks were not associated with risk of gout (P for trend=0.99). The multivariate relative risk of gout according to increasing fifths of fructose intake were 1.00, 1.29, 1.41, 1.84, and 2.02 (1.49 to 2.75; P for trend Conclusions Prospective data suggest that consumption of sugar sweetened soft drinks and fructose is strongly associated with an increased risk of gout in men. Furthermore, fructose rich fruits and fruit juices may also increase the risk. Diet soft drinks were not associated with the risk of gout.
- Open Access
- 29 January 2008
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 47 (5) , 713-717
Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels--the Third National Health and Nutrition Examination Survey
Objective. To evaluate haemoglobin A1c (HbA1c), fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels in a nationally representative sample of men and women. Methods. Using data from 14 664 participants aged 20 yrs and older in The US Third National Health and Nutrition Examination Survey (1988–1994), we examined the relation between the levels of HbA1c, other biomarkers and serum uric acid levels using multivariate linear regressions stratified by gender. Results. The serum uric acid levels increased with increasing serum HbA1c levels up to the category of 6–6.9%, and thereafter decreased with further increasing HbA1c levels (a bell-shaped relation). Compared with a HbA1c level of ≥9%. The corresponding multivariate differences among men were 8.3 μmol/l (95% CI −3.0, 19.6) and −64.8 μmol/l (95% CI −46.0, −84.5), which were both significantly different from those among women (P-values for interaction by sex P-value for interaction, 0.007). Serum uric acid levels increased linearly with increasing fasting serum C-peptide levels, serum insulin levels or insulin resistance (multivariate P-values for trend, Conclusions. Individuals with moderately elevated HbA1c levels (i.e. pre-diabetes) may be at a higher risk of hyperuricaemia and gout, particularly in women, whereas individuals with diabetes or highly elevated HbA1c levels may be at a lower risk of these conditions, particularly in men.
- 29 January 2008
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 47 (5) , 713-717
Open AccessHaemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels--the Third National Health and Nutrition Examination Survey
Objective. To evaluate haemoglobin A1c (HbA1c), fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels in a nationally representative sample of men and women. Methods. Using data from 14 664 participants aged 20 yrs and older in The US Third National Health and Nutrition Examination Survey (1988–1994), we examined the relation between the levels of HbA1c, other biomarkers and serum uric acid levels using multivariate linear regressions stratified by gender. Results. The serum uric acid levels increased with increasing serum HbA1c levels up to the category of 6–6.9%, and thereafter decreased with further increasing HbA1c levels (a bell-shaped relation). Compared with a HbA1c level of ≥9%. The corresponding multivariate differences among men were 8.3 μmol/l (95% CI −3.0, 19.6) and −64.8 μmol/l (95% CI −46.0, −84.5), which were both significantly different from those among women (P-values for interaction by sex P-value for interaction, 0.007). Serum uric acid levels increased linearly with increasing fasting serum C-peptide levels, serum insulin levels or insulin resistance (multivariate P-values for trend, Conclusions. Individuals with moderately elevated HbA1c levels (i.e. pre-diabetes) may be at a higher risk of hyperuricaemia and gout, particularly in women, whereas individuals with diabetes or highly elevated HbA1c levels may be at a lower risk of these conditions, particularly in men.
- Top Cited PapersOpen Access
- 13 August 2007
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 167 (15) , 1670-1675
Obesity, Waist Circumference, Weight Change, and the Risk of Psoriasis in Women
Psoriasis is a chronic, inflammatory disease of the skin that affects approximately 2% of the population1-4 and poses a lifelong burden for those affected.3 A survey by the National Psoriasis Foundation found that 75% of patients with psoriasis reported a moderate to large negative impact of the disease on the quality of their life, with an alteration of everyday activities.5 The negative impact of psoriasis may not be limited to its cutaneous or psychosocial manifestations. A recent large cohort study based on the General Practice Research Database in the United Kingdom found psoriasis to be an independent risk factor for myocardial infarction.6 Higher adiposity may increase the risk of psoriasis, but, to our knowledge, no prospective data are available. Clinicians have observed the association between obesity and psoriasis for years; several recent studies have confirmed a cross-sectional association between the two.7,8 For example, the prevalence of obesity in the patients with psoriasis in the Utah Psoriasis Initiative study was approximately twice that in the general population (34% vs 18%; P < .001).7 An Italian case-control study found a similar association.9 Overproduction of inflammatory cytokines such as tumor necrosis factor α (TNF-α), interleukin (IL)-1, IL-6, and IL-8 in adipose tissue is an important feature of obesity and may account for the pathogenesis of psoriasis.4,10 The state of obesity was speculated to provide a chronic level of low-grade inflammation that not only may contribute to the risk of psoriasis but also may account for its severity.10 Given the growing epidemic of obesity11 in recent years and its associated negative health effects,12,13 an accurate understanding of the impact of adiposity on psoriasis is important from the public health perspective as well as for comprehensive management of the condition. To address these issues, we prospectively evaluated the relationship between BMI (calculated as weight in kilograms divided by height in meters squared), weight change, waist circumference, hip circumference, waist-hip ratio, and incident psoriasis in a cohort of 78 626 women with no history of psoriasis.
- 13 August 2007
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 167 (15) , 1670-1675
Top Cited PapersOpen AccessObesity, Waist Circumference, Weight Change, and the Risk of Psoriasis in Women
Psoriasis is a chronic, inflammatory disease of the skin that affects approximately 2% of the population1-4 and poses a lifelong burden for those affected.3 A survey by the National Psoriasis Foundation found that 75% of patients with psoriasis reported a moderate to large negative impact of the disease on the quality of their life, with an alteration of everyday activities.5 The negative impact of psoriasis may not be limited to its cutaneous or psychosocial manifestations. A recent large cohort study based on the General Practice Research Database in the United Kingdom found psoriasis to be an independent risk factor for myocardial infarction.6 Higher adiposity may increase the risk of psoriasis, but, to our knowledge, no prospective data are available. Clinicians have observed the association between obesity and psoriasis for years; several recent studies have confirmed a cross-sectional association between the two.7,8 For example, the prevalence of obesity in the patients with psoriasis in the Utah Psoriasis Initiative study was approximately twice that in the general population (34% vs 18%; P < .001).7 An Italian case-control study found a similar association.9 Overproduction of inflammatory cytokines such as tumor necrosis factor α (TNF-α), interleukin (IL)-1, IL-6, and IL-8 in adipose tissue is an important feature of obesity and may account for the pathogenesis of psoriasis.4,10 The state of obesity was speculated to provide a chronic level of low-grade inflammation that not only may contribute to the risk of psoriasis but also may account for its severity.10 Given the growing epidemic of obesity11 in recent years and its associated negative health effects,12,13 an accurate understanding of the impact of adiposity on psoriasis is important from the public health perspective as well as for comprehensive management of the condition. To address these issues, we prospectively evaluated the relationship between BMI (calculated as weight in kilograms divided by height in meters squared), weight change, waist circumference, hip circumference, waist-hip ratio, and incident psoriasis in a cohort of 78 626 women with no history of psoriasis.